

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HealthyWay Inc.
健康之路股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2587)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

This announcement is made by HealthyWay Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company and potential investors with information on recent business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the project “Construction and Validation of Intelligent Service Platform for Liver Diseases” (the “**Project**”), which was submitted by the team led by Professor Jia Ji-Dong of Beijing Friendship Hospital of Capital Medical University together with the Group, has been successfully selected as one of the first batch of projects under the Proof-of-Concept Programme for Digital Healthcare in Chaoyang District, Beijing. This Project seeks to establish China’s first comprehensive liver disease management platform, leveraging AI large models and intelligent agent technologies, to support the World Health Organization (WHO) goal of eliminating viral hepatitis by 2030.

The Project is led by Professor Jia Ji-Dong, a highly regarded hepatologist and researcher specializing in liver diseases, whose team has led multiple national-level research projects and contributed to the development of international and domestic guidelines in the management of liver diseases.

The Project integrates the Group’s AI model and Chaoyang District’s medical big data to build a comprehensive framework for the full-cycle management of liver diseases.

It is expected that this Project will generate stable revenue and provide a new source of income to the Group.

The Board believes that this Project marks a major step for the Group in the field of AI powered specialized disease management, integrating artificial intelligence (AI) with specialized disease management systems, and is expected to become a benchmark case for AI powered specialized disease management. Going forward, the Group intends to leverage its experience in this Project to develop similar models and apply to other chronic diseases, such as diabetes, hypertension, and kidney disease, thereby consolidating its leading position in the digital health and wellness industry in China.

The Board will continue to monitor the progress of this Project and update potential investors and shareholders of the Company on any major progress.

Shareholders and potential investors of the Company are cautioned not to unduly rely on the above information and are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board

HealthyWay Inc.

Zhang Wanneng

Chairman, Chief Executive Officer and Executive Director

Fuzhou, the PRC, 16 June 2025

As at the date of this announcement, the Board comprises Mr. Zhang Wanneng and Mr. Chen Jing as executive directors; Mr. Chen Yong and Mr. Zhang Xiangming as non-executive directors; and Mr. Xu Jing, Dr. Lu Tao and Ms. Deng Xiaolan as independent non-executive directors.